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ABSTRACT 
 
Purpose: We previously demonstrated that converting patients from the enzyme-
inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine 
reduces serum lipids and C-reactive protein (CRP). We sought to determine if the same 
changes would occur when patients were switched to topiramate, which has shown 
some evidence of enzyme induction at high doses. We also examined the effects of 
drug switch on low-density lipoprotein (LDL) particle concentration. 
 
Methods: We converted 13 patients from phenytoin or carbamazepine monotherapy to 
topiramate monotherapy (most at doses of 100-150 mg/day). Fasting lipids, including 
LDL particle concentration, and CRP were obtained before and ≥6 weeks after the 
switch. A group of normal subjects had the same serial serologic measurements to 
serve as controls. 
 
Results: Conversion from inducers to topiramate resulted in a -35mg/dL decline in total 
cholesterol (p=0.033), with significant decreases in all cholesterol fractions, 
triglycerides, and LDL particle concentration (p≤0.03 for all), as well as a decrease of 
over 50% in serum CRP (p<0.001). Alterations in cholesterol fractions and CRP 
remained significant when compared to those seen in normal controls. 
 
Conclusions: Changes seen when inducer-treated patients are converted to TPM 
closely mimic those seen when inducer-treated patients are converted to lamotrigine or 
levetiracetam. These findings provide evidence that CYP450 induction elevates CRP 
and serum lipids, including LDL particles, and that these effects are reversible upon 
deinduction. Low-dose TPM appears not to induce the enzymes involved in cholesterol 
synthesis. 
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INTRODUCTION 
 
Antiepileptic drugs (AEDs) that induce the cytochrome P450 
(CYP450) system alter metabolism in a variety of ways that may become 
apparent when patients are started on or taken off these drugs. Patients 
switched from the enzyme-inducing agents phenytoin (PHT) or 
carbamazepine (CBZ) to the non-inducing drugs levetiracetam (LEV) or 
lamotrigine (LTG) experience a sizable drop in serum lipids, along with 
changes in other serologic indices of vascular risk, including C-reactive 
protein (CRP)(Mintzer et al., 2009). Other studies have suggested that 
patients treated with PHT or CBZ may have higher lipid levels than 
controls; at least one such study measured before and after treatment and 
found that CBZ produced significant elevation of lipids(Bramswig et al., 
2003; Nikolaos et al., 2004). Furthermore, the potent CYP450 inhibitor 
ketoconazole has been shown to reduce cholesterol production in 
experimental animals(Gibbons, 2002), and this effect is corroborated 
clinically by the finding that patients taking valproate, an AED with CYP450-
inhibiting properties, have lower cholesterol levels than controls(Nikolaos et 
al., 2004). These findings imply that serum lipids  — and possibly CRP —  
parallel the activity of the CYP450 enzyme system, so that treatment with a 
CYP450 inducing agent increases lipids, and upon withdrawal of the drug 
they return to the patient’s baseline.  
A number of the older AEDs — including PHT, CBZ, phenobarbital 
and primidone — are well-known to be potent CYP450 inducers, while 
many of the newer-generation agents — such as LEV, LTG, or gabapentin 
— clearly have no CYP450 effects. For some of the newer agents, 
however, the situation with regard to CYP450 effects is less clear-cut. For 
example, oxcarbazepine (OXC) has been shown to induce CYP3A4 and 
  
3A5, leading to important drug interactions, and it also likely induces the 
metabolism of vitamin D(Mintzer et al., 2006). Yet it appears not to have 
effects on lipids like those of CBZ(Isojarvi et al., 1994), suggesting that it 
shares some of the metabolic effects of enzyme inducing agents, but not all 
of them. 
Here we describe the effects on lipids and CRP when patients are 
switched from either CBZ or PHT to topiramate (TPM), a newer-generation 
AED that is widely used for both seizures and migraines. TPM induces at 
least some CYP450 enzymes at high doses(Rosenfeld et al., 1997), but there 
is no evidence of any CYP450 induction when it is used at low to moderate 
doses(Doose et al., 2003). Its effects on lipids relative to those of other AEDs 
have not been studied but are pertinent to the care of patients who are 
chronically treated with the drug. In addition to measurements of traditional 
lipid fractions, CRP, and lipoprotein(a), we also present data on changes in 
low-density lipoprotein (LDL) particle concentration, as this measure, which 
is distinct from the measurement of the amount of cholesterol carried by 
LDL particles (LDL-C), may have independent predictive power for 
myocardial infarction(Rosenson et al., 2002). 
 
 
METHODS 
 
Subjects 
 
The study involved 13 patients from the Jefferson Comprehensive 
Epilepsy Center or Thomas Jefferson University Hospital who were a) 
being treated with PHT or CBZ in monotherapy for at least 1 month and b) 
being crossed over to monotherapy with TPM based upon the 
recommendation of the treating epileptologist at our center. Drug 
  
conversion was undertaken due to incomplete seizure control, side effects, 
or concerns about the long-term effects of enzyme-inducing AED 
treatment. Of these 13 patients, one was being treated with fenofibrate 
(which is not subject to CYP450 induction) and another was taking 
fluvastatin and ezetimibe; the latter patient was excluded from 
measurement of traditional lipid fractions. All other patients were taking no 
lipid-lowering agents. As a comparator group, we utilized the same cohort 
of 16 normal control subjects described in our previous report who were not 
being treated with any anticonvulsant or lipid-lowering medications(Mintzer 
et al., 2009). These subjects provided fasting blood samples for the same 
serologic measures on two occasions approximately 10 weeks apart. 
 
Protocol 
 
Each subject provided two fasting blood samples: one while still on 
treatment with the old (enzyme-inducing) AED, and one after switch to TPM 
monotherapy. The latter sample was obtained at least 6 weeks after the 
last dose of the old AED to ensure sufficient time for complete de-induction 
of the CYP450 system. The schedule for conversion from the older drug to 
TPM was individually determined by the patient’s treating epileptologist. 
The target dose of TPM was also determined by the patient’s treating 
physician based upon perceived clinical need; this was 50-75 mg twice 
daily in all cases except for a single patient who was titrated up to 150 mg 
twice daily. Subjects were instructed to fast at least 10 hours prior to each 
blood draw, and samples were analyzed for lipid factions, lipid particle 
concentrations, and Lp(a), as well as for the serum level of the AED the 
patient was taking at that time. 
Lipid measurements were performed by a specialty lipid laboratory 
(Liposcience, Raleigh, NC). The analytical specifications are as 
  
documented in our previous investigation(Mintzer et al., 2009). LDL-C was 
measured directly rather than being calculated using the Friedwald formula. 
Lipid particle concentrations were measured using  a nuclear magnetic 
resonance spectroscopy technique, yielding a signal which can resolve the 
different classes of lipoproteins with a high degree of accuracy. Drug levels 
were performed at the Thomas Jefferson University Hospital laboratory. 
 
Statistical analysis 
 
Data were analyzed using a general linear model when they were 
normally distributed; where examination of residuals suggested non-
Gaussian distribution due to outliers, which was the case for total 
cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C), robust 
MM regression was utilized instead(Yohai, 1987). Lp(a) is well-known to 
have a non-normal distribution, so log transformation was used for these 
data prior to calculation of the change between draw 1 and draw 2. The 
mean change from draw 1 to draw 2 was calculated for each measure in 
each subject, with comparison then made between the patients and the 
normal subjects for each measure. In addition, all models controlled for the 
baseline (draw 1) value (with slopes permitted to differ among the two 
groups of subjects if those slopes were found to be significantly different). 
The numbers reported for within group change from draw 1 to draw 2 
reflect the predicted change in an individual measure given the average 
draw 1 value for the group. Between-group comparison is based on 
simultaneous testing of the difference in slopes and intercepts of the 
regression on draw 1 when slopes were found to be significantly different. 
Otherwise the regression lines are parallel with the same slope and 
between-group comparison is the usual comparison of the intercepts. No 
corrections were made for multiple comparisons since many of these 
  
measures are dependent upon each other. Data were analyzed in SAS 9.1 
(SAS Institute, Cary, NC) and S-Plus (Insightful Corporation, Seattle, WA). 
 
 
RESULTS 
 
Baseline characteristics 
 
Of the 13 patients completing the study, 6 were switched from CBZ to 
TPM and 7 were switched from PHT to TPM. Five of the CBZ-treated 
patients and 2 of the PHT-treated patients were female. The mean age of 
the whole cohort was 54 years (range 22 - 88). They had been treated with 
CBZ or PHT for anywhere between 30 days and 35 years. In the CBZ-
treated patients, drug levels at baseline ranged from 5.5 to 10.4 µg /mL 
(mean: 7.6). In the PHT-treated patients, drug levels ranged from 8.9 to 
30.1µg /mL  except for a single patient with a level of 3.3µg /dL (mean: 14.0 
µg /mL). The second blood draw was always obtained at least 6 weeks 
after the last dose of the enzyme-inducing AED; the total time between 
draws also included a period of several weeks to titrate up TPM and then 
titrate down the old drug.  The time between the first and second blood 
draws in these patients ranged from 76 to 301 days (mean: 169 days). The 
normal comparator group (n=16), described in the previous publication 
(Mintzer et al., 2009), was 50% female, with a younger mean age (39 
years) than these study subjects; however, neither age nor gender was a 
significant covariate for any of the study variables, so the reported results 
are unadjusted for these. 
 
Standard lipid measures 
  
 
Data on standard lipid measures for patients (n=12) and normal 
controls (n=16) are presented in the Table. (Note that when the same raw 
data for normal subjects is analyzed together with a different drug-treated 
group, the model-predicted values are slightly different; thus, the numbers 
for the normal subjects differ a bit from those presented in the previous 
paper, even though it is the same data.) Total cholesterol (TC) declined a 
mean of 35 mg/dL in the epilepsy patients after switch to TPM (p=0.033; 
Fig. 1). This decline was significantly reflected in all lipid fractions, including 
non-HDL-C (-18 mg/dL, p=0.011),  LDL-C (-18 mg/dL, p=0.023), serum 
triglycerides (TRIG)(-54 mg/dL, p<0.001), and HDL-C (-10 mg/dL, 
p=0.001). The single patient who was switched to high-dose TPM, with one 
of the higher TPM levels in the study, had a decline of 37mg/dL in TC after 
switch. 
When the changes observed in the drug-treated patients were 
compared to those seen in the normal subjects, there was a trend toward a 
larger decline in TC and a strong trend toward a larger decline in non-HDL-
C among the patients (p=0.09 and 0.051 respectively), while the changes  
LDL-C, HDL-C, and non-HDL-C were significantly greater in the patients 
(p=0.019, 0.024, and 0.051 respectively).  
 
Additional vascular risk markers 
 
Data regarding non-traditional vascular risk markers for patients 
(n=13) and controls are also presented in the Table. Lp(a) did not decline 
significantly after drug switch. LDL particle concentration declined 
significantly in the patients after switch to TPM (-21%, p=0.002). The 
change in Lp(a) remained marginally significant when compared to the 
change seen in the normal subjects (p=0.09). CRP dropped by more than 
  
half after switch to TPM (-59%; p=0.001), a change which remained 
significant in comparison to the change seen in the normal subjects 
(p=0.018). The decline was highly consistent between patients (Fig. 2). 
 
 
DISCUSSION 
 
 This is, to our knowledge, the first study to directly compare lipid 
levels under TPM treatment to those obtained under treatment with other 
AEDs. It is also the first to report CRP levels in TPM-treated patients, and 
the first to report LDL particle concentration in any epilepsy or AED-treated 
patients. Our findings indicate that patients switched from the enzyme-
inducing drugs PHT or CBZ to the newer-generation agent TPM experience 
substantial declines in both CRP and serum lipids, including LDL particles. 
The significance of the findings in spite of the modest sample size attests to 
the robust nature of the effect. 
 Lipid levels in TPM-treated neurological patients have been examined 
in few previous investigations, only one of which was in adults with 
epilepsy; that study included only female patients(Franzoni et al., 2007; 
Kocer et al., 2008; Genc et al., 2010). These studies found no change in 
TC after TPM treatment; one found a small decline in HDL-C only(Genc et 
al., 2010). Thus, it is unlikely that TPM itself produces a significant effect 
upon serum lipids. Furthermore, the results of the present study are quite 
comparable to those seen when patients are switched from inducers to 
LEV or LTG(Mintzer et al., 2009), two drugs which are both structurally and 
biochemically unrelated to TPM. This provides additional strong evidence in 
a separate group of patients in favor of the hypothesis that CYP450-
  
inducing agents increase lipid levels, so that switching to non-inducing 
drugs results in deinduction and a return to baseline values. 
 Additionally, these data, combined with those of previous studies, 
suggest that TPM at the doses studied here (predominantly 100-150 mg 
daily) may not affect the activity of the CYP450 system, at least with regard 
to the enzymes responsible for cholesterol synthesis. This is clinically 
relevant, since TPM has been found to induce the metabolism of oral 
contraceptive hormones at high doses, but not at low doses(Rosenfeld et 
al., 1997; Doose et al., 2003), making it unclear whether its effects on the 
CYP450 system are dose-dependent, enzyme-specific, or both. It is 
noteworthy that the single patient in the study who was switched to high-
dose TPM (300mg daily), and who had one of the higher TPM levels in the 
patient cohort, nonetheless had a drop of 37mg/dL in TC, suggesting that 
the drug may not affect the cholesterol synthetic pathways even at high 
doses. It is possible that the CYP450-inducing effects of TPM are both 
enzyme- and concentration-specific, occurring only for certain enzymes, 
and even then only at certain serum levels. Targetted study of patients 
taking high-dose TPM is clearly needed to establish this. 
 While involvement of the CYP450 system in cholesterol synthesis 
and metabolism is well-established, this is not the case for the synthesis of 
CRP, whose metabolic pathways remain somewhat obscure. CRP has 
recently been shown to be elevated in patients with epilepsy relative to 
controls(Tan et al., 2009), but our previous investigation, to our knowledge, 
is the only one that has examined this phenomenon in a drug-specific 
fashion(Mintzer et al., 2009). The current findings reinforce those of the 
previous study, demonstrating that conversion of patients from inducers to 
TPM results in sharp declines in CRP similar to those seen when patients 
are switched to LTG or LEV.  As with lipids, this indirectly but strongly 
supports the idea that CYP450 induction increases CRP, and that CRP 
  
levels decline after switch to a non-inducer through de-induction. It remains 
unclear whether the rise in CRP prompted by enzyme-inducing agents 
reflects broader upregulation of inflammatory pathways or an isolated 
epiphenomenon.  
 This is, to our knowledge, the only study that has ever examined LDL 
particle concentration in patients with epilepsy or in patients taking AEDs. 
The measurement of LDL particles is likely a more accurate reflection of an 
atherogenic diathesis than the standard measurement of LDL-C(El 
Harchaoui et al., 2007); the latter is, in effect, a surrogate marker for the 
former, which until relatively recently was not measurable in an 
economically feasible manner. The analogy is sometimes made to 
automotive travel, with LDL particles carrying cholesterol the way cars carry 
passengers; measuring LDL-C is like measuring the number of people 
traveling on a highway, when what one really wants to know is the number 
of vehicles. In a similar vein, evidence suggests that LDL particle 
concentration has predictive power for cardiovascular events over and 
above that provided by the measurement of LDL-C and other traditional risk 
factors(Rosenson et al., 2002; Cromwell and Otvos, 2004). The present 
data demonstrate that there is a significant decline in LDL particle number 
when patients are switched from inducers to TPM, corroborating that there 
is a significant improvement in atherogenic lipid fractions following CYP450 
deinduction. 
 One factor that is unique to TPM among available AEDs is its 
proclivity to reduce body weight(Verrotti et al, 2011). Weight loss itself may 
have a modest downward effect on serum lipids and CRP, so that it is 
possible that some of the effects observed in the present study could be 
due not just to CYP450 de-induction, but also to positive effects of TPM on 
these markers. Unfortunately some of our study subjects provided blood 
samples at outside laboratories because they lived too far away to return to 
  
our center, and this precluded the implementation of body weight 
measurement into our protocol. But the results obtained in the present 
patients are similar to those seen in other patients who were switched to 
LTG or LEV, both of which are weight-neutral drugs(Mintzer et al., 2009). 
Thus, we believe it is unlikely that the weight loss effects of TPM are a 
major contributor to our findings. 
 In sum, our results demonstrate that patients taking CBZ or PHT 
experience substantial declines in multiple markers of vascular risk when 
switched to TPM, similar to those engendered by switch to LEV or LTG. 
There are declines in HDL-C as well, but these are likely to be 
overwhelmed by the negative effects on pro-atherogenic markers (non-
HDL-C, TRIG, LDL particles, CRP). Thus, patients may be at higher risk for 
ischemic co-morbidities while under treatment with the former agents than 
while under treatment with TPM or other newer-generation, largely non-
inducing drugs. Epidemiologic studies will be necessary to determine 
whether these serologic changes correspond to increases in endpoint 
clinical events such as myocardial infarction or stroke. Based upon our 
data, there is no reason to believe that the use of low-dose TPM  in 
neurologic practice would increase the risk of ischemic vascular disease. 
Thus, there is good reason to believe that the differences between AEDs in 
serologic risk factors demonstrated here (and in previous studies) are 
clinically important. 
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TABLE 
 
Table: Lipid data in patients switched from an enzyme-inducing 
antiepileptic drug to topiramate 
 
 
     
 
 Outcome  
(mg/dL except as 
indicated) 
 Group  N 
 Draw 1 Mean  
(95% CI)  
Change from Draw 1 
to Draw 2 
 (95% CI)   
p-value 
(within 
group) 
p-value 
(between 
groups) 
Total Cholesterol   Normals 16 203   (180, 227)  -9    (-35, +17)  0.473 
       
 
Patients    12 227   (201, 253) -35    (-66, -3) 
 0.033  0.090 
Non-HDL-C       Normals 16 149   (127, 170)  -5     (-17,  +6)  0.371 
       
 
Patients    12 173   (151, 195) -18    (-31, -4) 
 0.011  0.051 
LDL-C   Normals 16 137   (116, 158) -11       (-24, 3)  0.115 
       
 
Patients    12 143   (121, 166) -18     (-34, -3) 
 0.023 
 0.019 
HDL-C         Normals 16  54      (48, 61)  -1       (-6,+ 4)  0.664 
       
 
Patients    12  54     (45,  62)  -10      (-16, -4) 
 0.001 
 0.024 
Triglyceride Normals 16 118    (81, 155) -11   (-32,  11)  0.305 
       
 
Patients    12 182   (125, 238) -54   (-78, -29) 
 <0.001  0.518 
Lp(a)† Normals 16  11      (7, 18)   -3% (-20%, +17%)  0.713 
       
 Patients 13  17      (8, 33)   -13% (-30%, +8%)  0.196 
 0.557 
LDL Particles†   Normals 16 1266 (1067, 1503)   -4% (-14%, +9%)  0.539 
       
(nmol/L) Patients    12 1574 (1346, 1841)   -21% (-31%, -9%) 
 0.002  0.090 
C-reactive protein†   Normals 16   1.93 (0.97, 3.82)   +7% (-27%, +57%)  0.717        
(mg/L) Patients    13   5.60 (2.14, 14.70)   -59% (-73%, -37%) 
 <0.001  0.018 
† Lp(a), LDL particle, and C-reactive protein data log transformed; means are geometric, with differences 
expressed as percentage change of ratio (draw 2/draw 1). Between-group p-values are as compared to the 
untreated subjects. 
HDL-C - high-density lipoprotein cholesterol. LDL - low density lipoprotein. LDL-C - low-density lipoprotein 
cholesterol. Lp(a) - lipoprotein(a). 
  
  
FIGURE LEGENDS 
 
Figure 1: Change in total cholesterol in patients switched from enzyme-
inducing AEDs to topiramate and in normal subjects. 
 
Each bar shows the percent change in total serum cholesterol between the first and 
second draws for a single subject, with drug-treated epilepsy patients shown in blue, 
and normal subjects not taking AEDs in yellow. 
 
 
 
 
 
 
Figure 2: Change in C-reactive protein in patients switched from enzyme-
inducing AEDs to topiramate and in normal subjects. 
 
 
Each bar shows the percent change in serum C-reactive protein between the first and 
second draws for a single subject, with drug-treated epilepsy patients shown in blue, 
and normal subjects not taking AEDs in yellow. (Note the one outlier whose CRP 
increased by 867%.) 
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